Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Bonny Deal: Wyeth Acquires Scottish Drug Discovery Firm Haptogen

This article was originally published in The Pink Sheet Daily

Executive Summary

Firm hopes to use Haptogen’s technology to generate novel protein therapeutics that can be made orally bioavailable, VP-Biologic Technologies Projan tells “The Pink Sheet” DAILY.

You may also be interested in...

When It Comes To Antibody Technology, Pfizer's On The Prowl

Pfizer's latest partnership in the space is with Theraclone Sciences, a Seattle start-up with an antibody technology that uses human B cells.

Forest Files Memantine/Donepezil Fixed Combination For Alzheimer’s

Commercialization of the fixed-dose combo buys lifecycle management for Forest and should support future drug development for partner Adamas, the originator of the technology behind the combination.





Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts